Our Science

Powerful innovation to transform MS

We're committed to rigorous and ongoing evaluation.

Browse our latest publications below.

Publication Category

Clinical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis

Study Published in Clinical Immunology

View Article

Compartmentalized complement activation is associated with cytokines CXCL-13, CXCL-9, Il-12b and paramagnetic rim lesions in multiple sclerosis

Research Presented at MSMilan 2023 - October 11-13

Download PDF

Performance Comparison of a Multi-Protein Multiple Sclerosis Disease Activity Test for Blood Serum Samples That Were Collected Before Versus After the MRI Scan

Research Presented at MSMilan 2023 - October 11-13

Download PDF

Lower arterial cerebral blood flow is associated with worse neuroinflammation and immunomodulation composite proteomic scores

Research Presented at MSMilan 2023 - October 11-13

Download PDF

CXCL-13, CXCL-9 and IL-12 cerebrospinal fluid levels predict higher disease activity and are associated with intrathecal IgM synthesis in multiple sclerosis

Research Presented at MSMilan 2023 - October 11-13

Download PDF

Real-World Utilization of a Proteomic Biomarker Panel for Assessing Multiple Sclerosis Disease Activity in an Academic Multiple Sclerosis Clinic with a Diverse Patient Population

Research Presented at MSMilan 2023 - October 11-13

Download PDF

Serum Biomarkers of Clinical and Radiographic Disease Progression in Multiple Sclerosis

Research Presented at MSMilan 2023 - October 11-13

Download PDF

Interpretable Thalamic Volume Charts in Multiple Sclerosis

Research Presented at MSMilan 2023 - October 11-13

Download PDF

Disagreement Among Neuroradiologists Detecting Change in Multiple Sclerosis Disease Activity

Research Presented at MSMilan 2023 - October 11-13

Download PDF

Disease Activity Score and Disease Pathway Scores Measured Using the Multiple Sclerosis Disease Activity Test are Significantly Reduced Prior to the Week 96 Dose for Patients Treated with Ublituximab in the Phase 3 ULTIMATE I and II Studies

Research Presented at MSMilan 2023 - October 11-13

Download PDF

1 - 10 of 70